Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $4.9 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 8.4% year-over-year to $4.9 billion; the TTM figure through Mar 2026 stood at $4.9 billion (up 8.4% YoY), while the FY2025 annual figure was $5.0 billion, up 12.84% from the prior year.
• Other Non-Current Liabilities slipped to $4.9 billion in Q1 2026, from $5.0 billion in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for BMY reached as high as $7.3 billion in Q1 2022 and fell as low as $4.5 billion in Q4 2024.
• The 5-year median for Other Non-Current Liabilities is $5.9 billion (2023), against an average of $5.8 billion.
• The widest YoY moves for Other Non-Current Liabilities: up 15.46% in 2025, down 33.5% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $6.6 billion in 2022, then slipped by 2.56% to $6.4 billion in 2023, then slumped by 30.4% to $4.5 billion in 2024, then increased by 12.84% to $5.0 billion in 2025, then slipped by 3.77% to $4.9 billion in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $4.9 billion, $5.0 billion, and $5.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.